β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation

Area of Science:

• Endocrinology
• Bone Biology
• Cell Signaling

Background:

• Thyrotropin (TSH) interacts with the TSH receptor (TSHR), a G protein-coupled receptor.
• TSHR activation is known to influence various cellular processes, with potential implications for bone health.

Purpose of the Study:

• To investigate the direct effects of TSH on osteoblast differentiation and signaling pathways.
• To elucidate the role of beta-arrestin proteins in mediating TSH-induced osteogenic effects.

Main Methods:

• Utilized engineered cell lines (HEK-TSHR and U2OS-TSHR) expressing the TSH receptor.
• Stimulated cells with TSH and a small molecule TSHR agonist (C2).
• Assessed protein kinase phosphorylation (AKT1, p38α, ERK1/2), gene expression (ALPL, RANKL, OPN), and beta-arrestin translocation via siRNA knockdown.

Main Results:

• TSH significantly upregulated phosphorylation of AKT1, p38α, and ERK1/2 in U2OS-TSHR cells, unlike the TSHR agonist C2.
• TSH increased the expression of osteoblast markers ALPL, RANKL, and osteopontin (OPN), with minimal effect from C2.
• TSH stimulated beta-arrestin-1 and -2 translocation to TSHR; beta-arrestin-1 knockdown inhibited TSH-induced signaling and osteoblast marker expression.

Conclusions:

• TSH directly enhances osteoblast differentiation in U2OS cells.
• Beta-arrestin-1 plays a crucial role in mediating TSH-induced signaling pathways that promote osteoblast differentiation and function.